Affy to Miss Q2 Guidance Due to Delayed Instrument Purchases, Declining Expression Sales
July 13, 2010
Affy to Miss Q2 Guidance Due to Delayed Instrument Purchases, Declining Expression Sales
Affymetrix expects to report second-quarter revenues of $71 million to $72 million, as much as 13 percent below guidance of $80 million to $82 million the company provided when it released its first-quarter results in April.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.